The Long Run with Luke Timmerman
"The Long Run" Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous. Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Episodes
Ep190: Neil Kumar on Building a Rare Disease Drug Company
Ep189: Marc Tessier-Lavigne on Reinventing Drug Discovery with AI
Xaira Therapeutics' CEO Marc Tessier-Lavigne discusses his career, ranging from neuroscience research to executive leadership in the biotech industry, and the company's AI-driven approach to drug discovery. He recounts his academic journey, influenced by philosophy and physics, leading to neuroscience. Xaira aims to tr...
Ep188: Art Krieg on Innate Immune System Activators for Cancer
Ep187: Eric Fischer on Creating a New Class of Medicines
Ep186: Bruce Levine & Mags McCarthy on a Song About Science and Hope
Ep185: Dr. Lachelle Weeks on Predicting Leukemia Risk At Scale
Ep184: Jen Adair on Affordable, Accessible Gene & Cell Therapies
Ep183: Sabah Oney on CAR-T Cells Against Solid Tumors
Ep182: Andy Rachleff & Yung Lie on Creative Ways to Back Science
Ep181: Claire Mazumdar on a Two-Pronged Attack Against Cancer
Ep180: John Rinn on Discovering Drugs Based on Long Non-Coding RNA
Ep179: Ethan Weiss & Josh Lehrer on a New Idea for Cardiovascular Disease & Diabetes
Ep178: Peyton Greenside on ML-Guided Biologics Discovery
Ep177: Kevin Parker on Finding Cancer Drug Targets
Ep176: David Roblin on Building a TechBio Company
Ep175: Andy Scharenberg on in vivo CAR-T cell therapies
Ep174: Najat Khan on the TechBio Movement
Ep173: Robert Blum on Building a Fully Integrated Biopharma For Muscle Disorders
Ep172: Mostafa Ronaghi on Studying Live Cells at Scale
Follow this podcast in Podwise
Sign in to get AI summaries, transcripts and mind maps for any episode, including new ones.
